The updated ASCO/CAP guideline recommendations for HER2 testing in the management of invasive breast cancer: a critical review of their implications for routine practice
(2014)
Journal Article
Rakha, E. A., Starczynski, J., Lee, A. H. S., & Ellis, I. O. (2014). The updated ASCO/CAP guideline recommendations for HER2 testing in the management of invasive breast cancer: a critical review of their implications for routine practice. Histopathology, 64(5), 609-615. doi:10.1111/his.12357
All Outputs (266)
Updated guideline recommendations for HER2 testing (2013)
Journal Article
Rakha, E. A., & Ellis, I. O. (2014). Updated guideline recommendations for HER2 testing. Nature Reviews Clinical Oncology, 11(1), 8-9. doi:10.1038/nrclinonc.2013.230
PIAS? expression in relation to clinicopathological, tumour factors and survival in indigenous black breast cancer women (2013)
Journal Article
Agboola, A., Musa, A., Banjo, A., Ayoade, B., Deji-Agboola, M., Nolan, C., …Green, A. (2014). PIASγ expression in relation to clinicopathological, tumour factors and survival in indigenous black breast cancer women. Journal of Clinical Pathology, 67(4), 301-306. https://doi.org/10.1136/jclinpath-2013-201658Aim: Indigenous black women with breast cancer (BC) show a high frequency of triple negative breast cancer (TNBC) comprising ER-, PR- and HER2- phenotypes and BRCA1 deficiency together with a high mortality rate, prompting speculation that risk facto... Read More about PIAS? expression in relation to clinicopathological, tumour factors and survival in indigenous black breast cancer women.
C-Met in invasive breast cancer: is there a relationship with the basal-like subtype? (2013)
Journal Article
Ho-Yen, C. M., Green, A. R., Brentnall, A. R., Rakha, E. A., Ellis, I. O., Kermorgant, S., & Jones, J. L. (2014). C-Met in invasive breast cancer: is there a relationship with the basal-like subtype?. Cancer, 120(2), 163-171. doi:10.1002/cncr.28386BACKGROUND Basal?like (BL) breast cancer is an aggressive form of breast cancer with limited treatment options. Recent work has identified BL breast cancer as a biologically distinct form of triple?negative breast cancer, with a worse outlook. The... Read More about C-Met in invasive breast cancer: is there a relationship with the basal-like subtype?.
Clinicopathological and molecular significance of Sumolyation marker (ubiquitin conjugating enzyme 9 (UBC9)) expression in breast cancer of black women (2013)
Journal Article
Agboola, A. J., Musa, A., Ayoade, B., Banjo, A., Anunobi, C., Deji-Agboola, A., …Green, A. (2014). Clinicopathological and molecular significance of Sumolyation marker (ubiquitin conjugating enzyme 9 (UBC9)) expression in breast cancer of black women. Pathology - Research and Practice, 210(1), 10-17. https://doi.org/10.1016/j.prp.2013.09.011The majority of breast cancers (BC) in Nigerian women are triple negative and show breast cancer-associated gene 1 (BRCA1) deficiency as well as the basal like phenotype, with a high mortality rate. In contrast to the well-defined predictive factors... Read More about Clinicopathological and molecular significance of Sumolyation marker (ubiquitin conjugating enzyme 9 (UBC9)) expression in breast cancer of black women.
A methodology to identify consensus classes from clustering algorithms applied to immunohistochemical data from breast cancer patients (2010)
Journal Article
Soria, D., Garibaldi, J. M., Ambrogi, F., Green, A. R., Powe, D., Rakha, E., …Ellis, I. O. (2010). A methodology to identify consensus classes from clustering algorithms applied to immunohistochemical data from breast cancer patients. Computers in Biology and Medicine, 40(3), https://doi.org/10.1016/j.compbiomed.2010.01.003Single clustering methods have often been used to elucidate clusters in high dimensional medical data, even though reliance on a single algorithm is known to be problematic. In this paper, we present a methodology to determine a set of ‘core classes’... Read More about A methodology to identify consensus classes from clustering algorithms applied to immunohistochemical data from breast cancer patients.